Importantly for glioma treatments, the clinical BET inhibitor OTX015 has been shown to pass the blood-brain-barrier [16], and HMBA can cause dose-limiting toxicities in CNS, suggesting it is also brain-penetrant [17–19]. Here, DNER is linked to central nervous system cancer.